| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
We previously reported that Lactoferrin (LF) could most likely be effective for preventing preterm delivery and intrauterine infections based on data derived from mice and rabbits. Here we describe six women with a history of multiple pregnancy losses or preterm delivery and refractory bacterial vaginosis, who received prebiotic LF therapy and delivered an infant normally.
Vaginal suppositories and oral prebiotic LF were administered to patients who were refractory to conventional treatment for vaginosis and had a history of late miscarriages and very early preterm delivery due to refractory vaginitis and chorioamnionitis. Lactoferrin significantly improved the vaginal bacterial flora. Lactobacillus that was detectable in the vaginas of all patients after one month of LF therapy gradually became dominant.
The findings from these patients suggest that administering LF to humans could help to prevent refractory vaginitis, cervical inflammation and preterm delivery.
|
